Brusatol enhances the chemotherapy efficacy of Cisplatin and Gemcitabine in KKU-100 cholangiocarcinoma cells through ROS-mediated apoptosis Authors: Tueanjai Khunluck, Ingon Inson, Chartinun Chutoe, Laddawan Senggunprai, Auemduan Prawan, Kornkamon Lertsuwan Published: 2026 ABSTRACT One of the main obstacles in Cholangiocarcinoma (CCA) treatment is drug resistant to the standard therapy, Cisplatin combined with Gemcitabine (Cis/Gem). Brusatol (Bru) has shown its potential in enhancing the effects of other chemotherapeutic drugs. Therefore, this study investigates the anti-cancer effects of Bru alone or combined with chemotherapeutic drugs, Cis and Gem, in human CCA cells (KKU-100), and explores the underlying mechanisms. Cell viability was determined using MTT assay, while intracellular reactive oxygen species (ROS) levels were measured using a DCFDA fluorescence assay. Apoptosis was assessed by caspase-3, -8, and -9 activity and annexin-V-FITC/propidium iodide (PI) double staining. Mitochondrial membrane potential (ΔΨm) was detected by JC-1 staining. Combination of Bru and Cis or Gem increased intracellular ROS levels, caspase-3, -8, and -9 activities, apoptotic cell population and the loss of ΔΨm in KKU-100 cells. This indicated the enhanced apoptotic effects of the combination therapy through the activation of both intrinsic and extrinsic pathways. Additionally, combination of Bru with Cis or Gem significantly reduced colony formation, and suppressed cell migration and invasion in KKU-100 cells. These findings support the potential of Bru as a promising anti-cancer agent or adjunct therapy to enhance current chemotherapy in CCA treatment.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1038/s41598-026-59031-7. Introduction Cholangiocarcinoma (CCA) is a highly aggressive malignancy of the bile duct1. It is a major health concern for populations in the Mekong basin region2,3. Although CCA is not the most common cancer worldwide, its incidence and mortality rates have been increasing4,5. In addition, CCA is notably difficult to diagnose and treat. It has been reported that CCA can be alleviated at early stages through surgical treatment. However, due to the challenges in diagnosing CCA, most patients are identified at an advanced stage, at which point surgery to remove the tumor is no longer an option6. Chemotherapy is one of the main alternatives for CCA treatments. Several chemotherapy regimens are used for advanced CCA. Cisplatin together with Gemcitabine (Cis/Gem) is commonly recommended as the first-line treatment in patients with advanced CCA7,8. The efficacy of this conventional chemotherapeutics; however, has been limited by drug resistance, which remains a major obstacle in CCA treatment. Consequently, studies on new therapeutic agents or novel regimens for CCA treatment are very important. Given that CCA typically carries a poor prognosis, tumors at advanced stage also exhibit a high metastatic potential to distant organs. This significantly impacts the overall survival of patients once metastasis has occurred. Metastasis is a complex, multistep process involving cancer cell adhesion, migration, intravasation, extravasation and colonization at secondary sites9. Therefore, an essential goal in cancer treatment is the effective suppression of tumor dissemination from the primary site and the prevention of metastasis, particularly in high-risk patients10. Suppressing metastasis has the potential to prolong survival and improve prognosis in patients with CCA. Consequently, the identification of novel biologically active molecules capable of disrupting the metastatic process represents a promising strategy for enhancing CCA treatment outcomes. In recent years, numerous compounds have been investigated for their potential use in cancer treatment10. Brusatol (Bru), an important triterpene lactone compound primarily isolated from Brucea javanica, is a natural quassinoid with various pharmacological properties including anti-inflammatory and anticancer effects11. Studies have shown that Bru can suppress cancer growth, induce apoptosis, and enhance the efficacy of chemotherapeutic agents (such as Gem, Cis, 5-fluorouracil, paclitaxel, carboplatin and etoposide) through multiple cellular mechanisms12–16. Our work is the very first study to investigate the combinatorial effect of Bru and the chemotherapeutic drugs, Cis and Gem, in human CCA cells. In this study, we explored the anticancer activities of Bru, both alone and combination with therapeutic agents including Cis and Gem, in human CCA cells. Additionally, the molecular mechanisms by which Bru exerts its anticancer effects and enhances chemosensitivity in cancer cell are investigated. Materials and methods Cell lines and culture conditions Human cholangiocarcinoma cells, KKU-100 (JCRB1568) and KKU-452 cells (JCRB1772) were acquired from the Japanese Collection of Research Bioresources (JCRB) Cell Bank (Osaka, JAPAN). These two cell lines were derived from a cholangiocarcinoma patient in an endemic region, which is highly relevant to the clinical and epidemiological context of cholangiocarcinoma in Southeast Asia17,18. The cells were grown in Ham’s F12 medium (Gibco, NY, USA), which was supplemented with 10% (v/v) fetal bovine serum (FBS) (Gibco, Texas, USA) and 1% penicillin–streptomycin (Gibco, NY, USA). Cells were maintained under an atmosphere of 5% CO2 at 37 °C and sub-cultured according to the manufacturer’s instruction. Chemicals Bru (SML1868), Cis (C2210000), Gem (Y0000675) and N-acetyl-L-cysteine (A7250) used in this study were purchased from Sigma-Aldrich. Cell viability assay Cholangiocarcinoma cell lines, KKU-100 and KKU-452, were seeded into 96-well tissue culture plates at a density of 1.0 × 104 cells/well. After cell attachment, the culture medium was replaced with serum-free Ham’s F12 medium containing Bru, Cis, Gem, NAC, or a combination of these compounds at the indicated concentrations for 24 and 48 h. Cell viability was assessed at the end of the treatment using the 3-(4,5-dimethylthiazol-2-yl)−2,5-diphenyltetrazolium bromide (MTT) colorimetric assay. In brief, the culture media was replaced with fresh serum-free Ham’s F12 medium containing 0.5 mg/mL MTT (Invitrogen, Oregon, USA), the cells were then incubated at 37 °C for 4 h. The MTT-containing medium was then removed, and the dimethyl sulfoxide (DMSO) was added to dissolve the formazan crystals. The optical density was measured at 595 nm using a microplate reader (MULTISKAN SkyHigh; Thermo Scientific). Cell viability was expressed as a percentage relative to untreated control cells. The half-maximal inhibitory concentration (IC50) of cells in response to the treatments were determined by using nonlinear regression analysis in GraphPad Prism 8 (GraphPad Software Inc.). For further clarification, the variable slope model of log (inhibitor) vs. normalized response was applied to calculate IC50 values. For conditions where the experimental data did not reach 50% inhibition, the IC50 were estimated by curve fitting based on the best-fit model. Annexin-V-FITC/propidium iodide (PI) double staining assay To investigate the apoptotic cells death after treatment, 3.3 × 105 KKU-100 cells were seeded into 6-well plates. Twenty-four hours after seeding, the cells were treated with Bru, Cis, Gem or the combination of these agents at the indicated concentrations for 48 h. Subsequently, apoptotic and necrotic cells were quantified using a FACScan flow cytometer (BD FACSCanto, BD Biosciences, San Jose, CA, USA) following double staining with Annexin-V-FITC (A13199, Invitrogen) and propidium iodide (PI) (P3566, Invitrogen). The proportions of cells in each phase were analyzed by using FACSDiva™ Software version 6.1.3 (BD Biosciences). Caspase-3, −8 and −9 activities assay Since caspase signaling plays a crucial role in regulating apoptotic cell death, the effects of Bru, alone and in combination with chemotherapeutic agents, Cis and Gem, were evaluated. Briefly, KKU-100 cells (1.0 × 106 cells) were seeded into 100-mm culture plate and incubated overnight for attachment. Following attachment, the cells were treated with Bru, Cis, Gem or the combination of these agents at the indicated concentrations for 12 h. After treatment, cells were collected washed with PBS wash prior to lysis. The supernatants were then incubated with caspase detection solution containing Z-DEVD-AMC for caspase-3 (Molecular Probes, Eugene, OR), Ac-LEHD-AFC for caspase-9 (EMD Millipore, Billerica, MA) and IETD-AFC for caspase 8 (ab39534) according to the manufacturers’ instructions. Fluorescence signals were measured using a microplate reader (Spark 10 M, Tecan, Austria) at 342/441(Ex/Em) for caspase-3 and 400/505 (Ex/Em) for caspase-8 and −9 activities. Clonogenicity survival assay KKU-100 cells were plated in 6-well tissue culture plates at 3.3 × 105 cells/well and incubated overnight. The cells were then exposed to Bru, Cis, Gem or the combination of these agents at the indicated concentrations for 48 h. After treatment, the viable cells were collected and plated into new 6-well tissue culture plates at 800 cells/well in 10% FBS Ham’F12 medium, where they were cultured for another 10 days. At the end of the experiment, the cells were washed twice with PBS, fixed in absolute methanol for 30 min, and stained with 0.5% crystal violet for 10 min at room temperature. The plates were then washed four times with tap water and air-dried. Colony formation number was quantified using ImageJ software (National Institutes of Health; NIH). DCFDA cellular ROS detection assay Cellular ROS levels were measured using 2´,7´-dichlorofluorescin diacetate (DCFDA) Cellular ROS detection assay kit (ab113851, Abcam, Cambridge, UK) according to the manufacturer’s instruction. In brief, KKU-100 cells were seeded into 96-black well plates with clear bottom at 2.5 × 104 cells/well and incubated overnight. Then, the cells were treated with Bru, Cis, Gem or the combination of these agents at the indicated concentrations. After 6 h of incubation, the fluorescence signal of DCF was measured using a multimode microplate reader (Tecan) at 485/535 (Ex/Em). Mitochondrial membrane potential assay Since dissipation of the mitochondrial electrochemical potential gradient is a key event in apoptosis, the change in mitochondrial transmembrane potential (ΔΨm) was evaluated. KKU-100 cells were seeded into 100-mm culture plate at 1.0 × 106 cells/plate, incubated overnight and then treated with Bru, Cis, Gem or the combination of these agents at the indicated concentrations for 12 h. Following treatment, ΔΨm was assessed using the MitoProbe JC-1 assay kit (MP34152, Thermo Fisher Scientific) according to the manufacturer’s protocol. In brief, treated cells were incubated with 2 μM JC-1 in all conditions, along with 50 μM carbonyl cyanide m-chlorophenyl hydrazone (CCCP) as a positive control for 30 min at 37 °C in 5% CO₂, Cells were then harvested by centrifugation, resuspended in PBS, and transferred to a 96-well tissue culture plate for analysis. ΔΨm was measured using a multimode microplate reader (Tecan), and images were captured using an AE31E inverted microscopes (Motic, China). JC-1 is a florescent dye that accumulates in mitochondrial in a potential-dependent manner. In healthy mitochondria, JC-1 forms aggregate that emit red florescence (Ex/Em = 535/595). In contrast, loss of ΔΨm causes JC-1 to remain in its monomeric form, emitting green florescence (Ex/Em = 485/535), which indicates mitochondrial dysfunction. Wound healing assay Cell migration was assessed using a wound healing assay, as described previously19. Briefly, KKU-100 cells were seeded into 24-well culture plates at 4.0 × 105 cells/well and incubated until a monolayer was formed. The cells were washed with PBS before introducing a wound with a sterile 200 µL pipette tip. Following wounding, the cells were treated with Bru, Cis, Gem or the combination of these agents at the indicated concentrations. A series of images of the scratched wound were then taken from 0 to 72 h after treatment. The closing of scratch wound, representing the migration process, was monitored by imaging sample of the denuded area along the scratch using an AE31E inverted microscopes (Motic, China). The wound closure area was quantified using ImageJ software (NIH). Cell migration ability was calculated as percentage of wound closure area relative to the initial scratch area. Transwell invasion assay The invasive ability of KKU-100 cells was evaluated using a Transwell chamber system. The upper side of 24-well polycarbonate filter inserts (8 μm pore size, Corning, NY, USA) was coated with Matrigel (356,234, Corning, USA), diluted at 1:5 ratio with serum-free Ham’s F12 medium. KKU-100 cells were then seeded into the upper chambers at 5.0 × 104 cells/well in serum-free Ham’s F12 medium, while the lower chambers were filled with 20% FBS in Ham’s F12 media to serve as a chemoattractant. Cells were treated with Bru, Cis, Gem or the combination of these agents at the indicated concentrations for 48 h. Following incubation, the invasive cells on the lower surface of the membrane were fixed with ice-cold absolute methanol for 20 min and stained with 0.5% crystal violet staining at room temperature for 15 min. The invaded cells on the lower surface of the filters were captured using an AE31E inverted microscopes (Motic, China). The number of invasive cells was quantified using ImageJ software (NIH). Statistical analysis All experiments were performed in three independent biological replicates, and the data were presented as mean ± SEM. Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison test. A p-value < 0.05 was considered as statistically significant. All statistical analyses were calculated using GraphPad Prism 8 (GraphPad Software Inc.). Results Bru suppresses CCA cell viability in a dose- and time-dependent manner To assess the potential cytotoxic effect of Bru on CCA cells, human poorly differentiated CCA cell lines, KKU-100 and KKU-452, were exposed to increasing concentrations of Bru for 24 and 48 h. Cell viability was then evaluated using the MTT assay. As shown in Fig. 1, the viability of both two cell lines was significantly reduced after the exposure of Bru in a dose-dependent manner. The decrease in cell viability correlated linearly with increasing concentrations of Bru. Considering the IC50 values, KKU-100 cells exhibited higher IC50 values reflecting its lower sensitivity to Bru than KKU-452 cells (Fig. 1 and Table 1). The cytotoxic effect exerted by Bru was dependent on the time of exposure as well. The IC50 values at 24 h in each of the cell lines was notably higher than that at 48 h (Table 1). Altogether, these results indicated that the cytotoxic effects of Bru in CCA cell lines were dose- and time-dependent. Due to its well-characterized molecular features, stable growth properties, and documented responsiveness to chemotherapeutic agents including Cis and Gem20–24, KKU-100 was selected for all subsequent experiments to further investigate the therapeutic potential of Bru.Fig. 1Cytotoxic effects of Bru on human CCA cell viability were measured by MTT assay. (A, B) KKU-100 and (C, D) KKU-452 cells were exposed to different concentrations of Bru for 24 or 48 h. The results were expressed as mean ± SEM of three independent experiments with two replicates each. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test. (****p < 0.0001 versus the control).Table 1The estimated IC50 values of Bru against CCA cell viability.Cell linesIC50 value of Bru (µM)24 h48 hKKU-100112.40.45KKU-4524.930.15 Cytotoxic effects of Bru on human CCA cell viability were measured by MTT assay. (A, B) KKU-100 and (C, D) KKU-452 cells were exposed to different concentrations of Bru for 24 or 48 h. The results were expressed as mean ± SEM of three independent experiments with two replicates each. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test. (****p < 0.0001 versus the control). Table 1The estimated IC50 values of Bru against CCA cell viability.Cell linesIC50 value of Bru (µM)24 h48 hKKU-100112.40.45KKU-4524.930.15 The estimated IC50 values of Bru against CCA cell viability. Bru enhanced chemotherapeutic agents, Cis and Gem, -mediated cytotoxicity in KKU-100 cells To evaluate whether Bru could enhance anticancer activity of standard chemotherapeutic agents, Cis and Gem, KKU-100 cells were treated with Bru, Cis, Gem or the combination of these agents for 24 and 48 h, followed by assessment of cell viability using the MTT assay. Cis and Gem-the current first-line regimen for advanced CCA-were used at sub-cytotoxic concentrations (5 µM and 1 µM, respectively), which were predetermined to induce less than 50% cell death (Fig. S1). The same concentrations were also used to determine drug combination effects in KKU-100 cells in previous studies25,26. Similar to Fig. 1, Bru was tested across a concentration range of 0.31–10 µM in combination with either Cis or Gem. The individual effects of each compound were included for comparison within the same experimental sets. As illustrated in Fig. 2A,B, the combination of Bru and 5 µM Cis significantly augmented their cytotoxicity in KKU-100 cells at both 24 and 48 h of treatments as compared to these agents alone. At 24 h, the combination treatments notably decreased KKU-100 cell viability to 37.51%, 38.25%, 43.26% and 42.92% when Bru at 0.63 µM, 2.5 µM, 5 µM and 10 µM was used (Fig. 2A). More drastic enhancement was noticed in the combined conditions at 48 h when 56.96% reduction (0.63 µM Bru + 5 µM Cis), 66.33% reduction (1.25 µM Bru + 5 µM Cis), 81.28% reduction (2.5 µM Bru + 5 µM Cis), 86.48% reduction (5 µM Bru + 5 µM Cis) and 85.67% reduction (10 µM Bru + 5 µM Cis) were found (Fig. 2B). Similarly, the combination of Bru and Gem significantly increased their cytotoxicity in KKU-100 cells at both 24 and 48 h of treatments. At 24 h of treatment, the combination treatments significantly reduced KKU-100 cell viability to 40.51%, 41.21%, and 45.39% when Bru at 0.31 µM, 0.63 µM and 10 µM was applied (Fig. 2C). Greater reduction of cell viability was found in the combination at 48 h of treatments when 63.97% reduction (5 µM Bru + 1 µM Gem) and 76.06% reduction (10 µM Bru + 1 µM Gem) were found (Fig. 2D). Collectively, these results demonstrated that concurrent exposure to Bru and either Cis or Gem significantly augmented their cytotoxic effect in KKU-100 cells, particularly at the combinations of 5 µM Bru + 5 µM Cis and 10 µM Bru + 1 µM Gem after 48 h of treatment. These conditions were therefore selected for subsequent mechanistic investigations.Fig. 2Sensitizing effect of Bru on Cis and Gem-induced cytotoxicity in human cholangiocarcinoma KKU-100 cells. Cell viability was analyzed by MTT assay after treatment with the combination of these compounds at indicated concentrations for 24 and 48 h. (A, B) Bru + Cis and (C, D) Bru + Gem. Bars represent the mean ± SEM of three independent biological replicates with two technical replicates each. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test. (****p < 0.0001 versus the control, while #p < 0.05, ##p < 0.01, ###p < 0.001, and ####p < 0.0001 versus compared group as indicated by straight line). Sensitizing effect of Bru on Cis and Gem-induced cytotoxicity in human cholangiocarcinoma KKU-100 cells. Cell viability was analyzed by MTT assay after treatment with the combination of these compounds at indicated concentrations for 24 and 48 h. (A, B) Bru + Cis and (C, D) Bru + Gem. Bars represent the mean ± SEM of three independent biological replicates with two technical replicates each. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test. (****p < 0.0001 versus the control, while #p < 0.05, ##p < 0.01, ###p < 0.001, and ####p < 0.0001 versus compared group as indicated by straight line). To quantitatively assess drug interactions, combination index (CI) values were calculated using the Chou–Talalay method27. CI values were calculated to assess drug interactions, where CI < 1 indicates synergism, CI = 1 indicates an additive effect, and CI > 1 indicates antagonism. It was found that the combination of 5 µM Bru + 5 M Cis yielded a CI value of 0.97, indicating a slight synergistic to nearly additive effect (Table 2). While the combination resulted in increased cytotoxic effects compared to single-agent treatments, the combination of 10 µM Bru + 1 µM Gem resulted in a CI value of 1.42, indicating an antagonistic interaction rather than synergism (Table 2). These results suggested that the effect of Bru in combination therapy is drug-dependent.Table 2Combination index (CI) analysis of Bru in combination with chemotherapeutic drugs, Cis and Gem in KKU-100 cells.Drug combinationCombination index (CI)5 µM Bru + 5 µM Cis0.9710 µM Bru + 1 µM Gem1.42 Table 2Combination index (CI) analysis of Bru in combination with chemotherapeutic drugs, Cis and Gem in KKU-100 cells.Drug combinationCombination index (CI)5 µM Bru + 5 µM Cis0.9710 µM Bru + 1 µM Gem1.42 Combination index (CI) analysis of Bru in combination with chemotherapeutic drugs, Cis and Gem in KKU-100 cells. Bru enhanced Cis and Gem- induced apoptosis in KKU-100 cells To explore whether the enhanced cytotoxicity observed in KKU-100 cells following combined treatment of Bru and the chemotherapeutic drugs, Cis and Gem, was associated with apoptosis, Annexin-V-FITC/PI dual staining assay was performed after 48 h of treatment. As shown in Fig. 3A, co-treatment with 5 μM Bru and 5 μM Cis significantly decreased the proportion of viable cells compared to the single agent treatments and the untreated control (Fig. 3B). This corresponded to a significant increase in the percentage of apoptotic cells, as indicated by Annexin-V positivity (Fig. 3D–F). In contrast, cells in necrotic phase in all treated groups remained unchanged as compared to the control (Fig. 3C). A similar trend was observed in the combination of 10 μM Bru and 1 μM Gem (Fig. 3G–L). Compared to either treatment alone, the combined condition significantly increased the percentage of apoptotic cells over the treatment period (Fig. 3J–L), while necrosis levels were unaffected (Fig. 3I). Taken together, these findings suggest that the enhanced cytotoxic effect induced by Bru in combination with Cis or Gem in KKU-100 cells is primarily mediated through the induction of apoptosis rather than necrotic cell death.Fig. 3Combining effects of Bru and chemotherapeutic drugs, Cis and Gem, induced apoptosis in KKU-100 cells. (A) Apoptotic cell death in KKU-100 cells after 48 h of treatment with 5 µM Bru, 5 µM Cis, or a combination of both agents and their quantified data was shown in (B) normal, (C) necrotic, (D) early apoptotic, (E) late apoptotic and (F) total apoptotic cells. (G) Apoptotic cell death in KKU-100 cells after 48 h of treatment with 10 µM Bru, 1 µM Gem, or a combination of both agents and their quantified data was shown in (H) normal, (I) necrotic, (J) early apoptotic, (K) late apoptotic and (L) total apoptotic cells. Bar graphs represent mean ± SEM of three independent biological experiments. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test. (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 versus control; while #p < 0.05, ##p < 0.01, and ###p < 0.001 versus compared group as indicated by straight line). Combining effects of Bru and chemotherapeutic drugs, Cis and Gem, induced apoptosis in KKU-100 cells. (A) Apoptotic cell death in KKU-100 cells after 48 h of treatment with 5 µM Bru, 5 µM Cis, or a combination of both agents and their quantified data was shown in (B) normal, (C) necrotic, (D) early apoptotic, (E) late apoptotic and (F) total apoptotic cells. (G) Apoptotic cell death in KKU-100 cells after 48 h of treatment with 10 µM Bru, 1 µM Gem, or a combination of both agents and their quantified data was shown in (H) normal, (I) necrotic, (J) early apoptotic, (K) late apoptotic and (L) total apoptotic cells. Bar graphs represent mean ± SEM of three independent biological experiments. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test. (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 versus control; while #p < 0.05, ##p < 0.01, and ###p < 0.001 versus compared group as indicated by straight line). Combination of Bru and chemotherapeutic drugs, Cis and Gem, enhances ROS Generation Since ROS generation is widely recognized as an upstream event that can trigger subsequent apoptotic and cytotoxic processes28, we further elucidate whether the apoptosis induced by the combined treatment of Bru and chemotherapeutic drugs, Cis and Gem, in KKU-100 cells was associated with the generation of cellular ROS, intracellular ROS levels were quantified following treatment at an early timepoint. TBHP was used as a positive control for ROS induction in the assay as it is a well-established oxidative stress inducer in cell-based ROS detection systems29. As shown in Fig. 4A, cellular ROS levels in the cells treated with 5 μM Bru or 5 μM Cis alone remained unchanged as compared to the untreated control. Notably, the combination of 5 μM Bru and 5 μM Cis markedly increased ROS accumulation relative to either single-agent treatment. Similarly, as presented in Fig. 4B, treatment with 10 μM Bru alone did not induce a significant change in ROS levels, whereas 1 μM Gem led to a moderate but significant increase in ROS compared to the control. Remarkably, co-treatment with 10 μM Bru and 1 μM Gem resulted in a robust and statistically significant elevation of ROS, exceeding the levels observed in cells treated with either agent alone.Fig. 4Cellular ROS was induced in KKU-100 upon Bru combinations. KKU-100 cells were treated for 6 h with (A) 5 µM Bru, 5 µM Cis or a combination of both agents, (B) 10 µM Bru, 1 µM Gem or a combination of both agents was quantified by DCFDA cellular ROS detection assay. Cells were treated with 200 µM TBHP (tert-butyl hydroperoxide) were used as positive control. (C, D) Cell viability was analyzed by MTT assay after treatment with 5 µM Bru, 5 µM Cis, 10 µM Bru, 1 µM Gem or 2 mM N-acetylcysteine (NAC) at indicated concentrations or the combination of these agents for 48 h. Bars represent the mean ± SEM of three independent biological replicates with two technical replicates each. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test. (*p < 0.05, **p < 0.01, and ****p < 0.0001 versus control; while #p < 0.05, ##p < 0.01, and ####p < 0.0001 versus compared group as indicated by straight line). Cellular ROS was induced in KKU-100 upon Bru combinations. KKU-100 cells were treated for 6 h with (A) 5 µM Bru, 5 µM Cis or a combination of both agents, (B) 10 µM Bru, 1 µM Gem or a combination of both agents was quantified by DCFDA cellular ROS detection assay. Cells were treated with 200 µM TBHP (tert-butyl hydroperoxide) were used as positive control. (C, D) Cell viability was analyzed by MTT assay after treatment with 5 µM Bru, 5 µM Cis, 10 µM Bru, 1 µM Gem or 2 mM N-acetylcysteine (NAC) at indicated concentrations or the combination of these agents for 48 h. Bars represent the mean ± SEM of three independent biological replicates with two technical replicates each. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test. (*p < 0.05, **p < 0.01, and ****p < 0.0001 versus control; while #p < 0.05, ##p < 0.01, and ####p < 0.0001 versus compared group as indicated by straight line). We further validated whether the intensified cellular ROS levels realized in the combined treatment of Bru and chemotherapeutic drugs, Cis and Gem, was responsible for the enhanced cytotoxicity. NAC, a well-known antioxidant and ROS scavenger, was added into the combined treatment of Bru and chemotherapeutic drugs, Cis and Gem, followed by the MTT assay. The results in Fig. 4C,D confirmed that the combination of 5 µM Bru + 5 µM Cis and 10 µM Bru + 1 µM Gem at 48 h significantly enhanced the cytotoxic effects on KKU-100 cells. NAC significantly decreased Bru-enhanced chemotherapeutic drugs, Cis and Gem, cytotoxicity compared to the combination of these drugs without NAC (Fig. 4C,D). Taken together, these results indicate that co-treatment with Bru and the chemotherapeutic agents, Cis and Gem, enhances cytotoxicity in KKU-100 cells through the induction of ROS accumulation. Combination of Bru and chemotherapeutic drugs, Cis and Gem, induced depolarization of mitochondrial transmembrane potential Given the mitochondria’s sensitivity to oxidative stress, we next investigated whether the elevated ROS levels observed following combined treatment with 5 µM Bru + 5 µM Cis and 10 µM Bru + 1 µM Gem impacted mitochondrial function, by assessing ΔΨm alteration using the JC-1 assay. As shown in Fig. 5A, mitochondria in untreated control cells showed red fluorescence, indicating accumulation of JC-1 aggregates in the healthy mitochondrial matrix. On the other hand, treating the cells with the compounds alone or the combination of these agents extensively induced the green fluorescence of JC-1 monomers in the cytosol. A decrease in the ratio of JC-1 aggregates/JC-1 monomers after various treatments indicated depolarization of ΔΨm. The combination of 5 µM Bru + 5 µM Cis significantly induced the loss of ΔΨm as compared to the cells treated with 5 µM Cis, while such the combination slightly decreased the ΔΨm as compared to the cells treated with 5 µM Bru alone (Fig. 5B). Likewise, the loss of ΔΨm was significantly observed in the cells exposed to the combination of 10 µM Bru + 1 µM Gem as compared to the cells treated with 1 µM Gem alone (Fig. 5B). Collectively, these findings suggest that Bru enhanced mitochondrial dysfunction-inducing agents in KKU-100 cells.Fig. 5Combining effects of Bru and chemotherapeutic drugs, Cis and Gem, on mitochondrial transmembrane potential (ΔΨm) in KKU-100 cells. The cells were incubated with 5 µM Bru, 5 µM Cis, 5 µM Bru + 5 µM Cis, 10 µM Bru, 1 µM Gem and 10 µM Bru + 1 µM Gem for 12 h following by JC-1 staining assay. (A) Fluorescent images of the cells stained with JC-1 dye are shown. (B) The relative ratio of J-aggregates/J-monomers was determined from JC-1 assay. Each column represents mean ± SEM from three independent experiments. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test. (****p < 0.0001 versus control; while #p < 0.05 and ##p < 0.01 versus compared group as indicated by straight line). Combining effects of Bru and chemotherapeutic drugs, Cis and Gem, on mitochondrial transmembrane potential (ΔΨm) in KKU-100 cells. The cells were incubated with 5 µM Bru, 5 µM Cis, 5 µM Bru + 5 µM Cis, 10 µM Bru, 1 µM Gem and 10 µM Bru + 1 µM Gem for 12 h following by JC-1 staining assay. (A) Fluorescent images of the cells stained with JC-1 dye are shown. (B) The relative ratio of J-aggregates/J-monomers was determined from JC-1 assay. Each column represents mean ± SEM from three independent experiments. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test. (****p < 0.0001 versus control; while #p < 0.05 and ##p < 0.01 versus compared group as indicated by straight line). Combination of Bru and chemotherapeutic drugs, Cis and Gem, induced apoptosis in KKU-100 by simultaneous activation of the extrinsic and intrinsic pathways To further elucidate the mechanisms underlying the enhanced apoptosis observed in KKU-100 cells following combined treatment of Bru and chemotherapeutic drugs, Cis and Gem, we investigated whether cell death was mediated via the extrinsic (death receptor-mediated) or intrinsic (mitochondrial) apoptotic pathway. In this experiment, the activities of the initiator caspases −8 and −9, as well as the effector caspase-3, were measured using a caspase activity assay. As shown in Fig. 6A–C, the combination of 5 µM Bru + 5 µM Cis and 10 µM Bru + 1 µM Gem significantly augmented the activity of caspase-3, −8 and −9 in KKU-100 cells as compared to individual treatments. The effector caspase-3 activity in the combination of 5 µM Bru + 5 µM Cis and 10 µM Bru + 1 µM Gem were increased by 3.2-fold and 4.1-fold, respectively (Fig. 6A). Likewise, the initiator capase-8 activity in the combination of 5 µM Bru + 5 µM Cis and 10 µM Bru + 1 µM Gem were increased by 1.5-fold and 1.7-fold, respectively (Fig. 6B). Similar results were observed in Fig. 6C, where the initiator capase-9 activity in the combination of 5 µM Bru + 5 µM Cis and 10 µM Bru + 1 µM Gem were risen close to 1.8-fold with 1.82-fold for Cis combination and 1.76-fold for Gem combination as compared with control. Together, these findings demonstrated that the combination of Bru and chemotherapeutic agents, Cis and Gem, induced apoptosis in KKU-100 cells through concurrent activation of both the extrinsic and intrinsic apoptotic pathways.Fig. 6Combining effects of Bru and chemotherapeutic drugs, Cis and Gem, increased caspase-3, −8 and −9 activities in KKU-100 cells. (A) Caspase-3, (B) Caspase-8 and (C) Caspase-9 activities in KKU-100 cells treated with 5 µM Bru, 5 µM Cis, 5 µM Bru + 5 µM Cis, 10 µM Bru, 1 µM Gem, or 10 µM Bru + 1 µM Gem for 12 h was quantified using specific fluorogenic substrates. Bar graphs represent mean ± SEM of three independent biological experiments. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test. (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 versus control; while #p < 0.05, ##p < 0.01, and ###p < 0.001 versus compared group as indicated by straight line). Combining effects of Bru and chemotherapeutic drugs, Cis and Gem, increased caspase-3, −8 and −9 activities in KKU-100 cells. (A) Caspase-3, (B) Caspase-8 and (C) Caspase-9 activities in KKU-100 cells treated with 5 µM Bru, 5 µM Cis, 5 µM Bru + 5 µM Cis, 10 µM Bru, 1 µM Gem, or 10 µM Bru + 1 µM Gem for 12 h was quantified using specific fluorogenic substrates. Bar graphs represent mean ± SEM of three independent biological experiments. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test. (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 versus control; while #p < 0.05, ##p < 0.01, and ###p < 0.001 versus compared group as indicated by straight line). Combination of Bru and chemotherapeutic drugs, Cis and Gem, suppressed KKU-100 colony formation Based on the preceding experiments, the combination of Bru and chemotherapeutic agents, Cis and Gem, significantly suppressed KKU-100 cell viability through apoptosis induction. However, it remained unclear whether the growth-inhibitory effects would persist in the surviving cell population following treatment withdrawal. To address this, a colony formation assay was performed to assess the long-term suppressive potential of these treatments. After KKU-100 cells were exposed to 5 µM Bru, 5 µM Cis, 5 µM Bru + 5 µM Cis, 10 µM Bru, 1 µM Gem, or 10 µM Bru + 1 µM Gem for 48 h, viable cells were seeded into the new 6-well tissue culture plates for colony formation assay. As shown in Fig. 7A, 5 µM Bru and 5 µM Cis strongly inhibited KKU-100 clonogenicity by 86.40% and 98.03%, respectively, as compared to the control. Importantly, the combined condition of 5 µM Bru + 5 µM Cis significantly inhibited colony forming ability of the cells as compared to cells treated with 5 µM Bru alone (Fig. 7A,B). Likewise, 10 µM Bru and 1 µM Gem notably diminished the number of KKU-100 colonies by 94.14% and 77.23% as compared to control (Fig. 7C). Interestingly, only a minimal number of colonies were detected in the combination of 10 µM Bru + 1 µM Gem (Fig. 7C,D). These findings demonstrated that both Bru and the standard chemotherapeutic agents, Cis and Gem, exhibited a strong long-term inhibitory effect on KKU-100 cell clonogenic potential, and the combination of these agents showed even more pronounced suppression.Fig. 7Combination of Bru and chemotherapeutic drugs, Cis and Gem, exhibited long-term inhibition on KKU-100 colony formation. Representative images of colony formation and their quantified colony formation number of KKU-100 exposed to (A, B) 5 µM Bru, 5 µM Cis and 5 µM Bru + 5 µM Cis, (C, D) 10 µM Bru, 1 µM Gem, and 10 µM Bru + 1 µM Gem. Bar graphs show mean ± SEM of three independent biological replicates with two technical duplicates each. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test. (****p < 0.0001 versus control; while #p < 0.05, ##p < 0.01, and ###p < 0.001 versus compared group as indicated by straight line). Combination of Bru and chemotherapeutic drugs, Cis and Gem, exhibited long-term inhibition on KKU-100 colony formation. Representative images of colony formation and their quantified colony formation number of KKU-100 exposed to (A, B) 5 µM Bru, 5 µM Cis and 5 µM Bru + 5 µM Cis, (C, D) 10 µM Bru, 1 µM Gem, and 10 µM Bru + 1 µM Gem. Bar graphs show mean ± SEM of three independent biological replicates with two technical duplicates each. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test. (****p < 0.0001 versus control; while #p < 0.05, ##p < 0.01, and ###p < 0.001 versus compared group as indicated by straight line). Combination of Bru and chemotherapeutic drugs, Cis and Gem, weakened the migrative and invasive capacity of KKU-100 cells Since the combined treatment markedly reduced cancer cell viability, we next investigated whether the combination of Bru and chemotherapeutic agents, Cis and Gem, could further suppress the metastatic potential of KKU-100 cells. Migratory ability of the cells exposed to treatments was assessed using wound healing assay. As compared to the control group, the percentage of wound closure, representing cell migration, was markedly and consistently reduced in KKU-100 cells treated with 5 µM Bru and 10 µM Bru at 24, 48, and 72 h. In contrast, 5 µM Cis significantly decreased cell migration only at 24 h. Although the effects did not reach statistical significance, the migration of cells exposed to Cis or Gem alone showed a decreasing trend at later time points. (Fig. 8). Interestingly, the combination of 5 µM Bru + 5 µM Cis resulted in a notably decreased cell migration at 48 and 72 h compared to individual drug (Fig. 8A,B). Likewise, significant cell migration suppression was observed in KKU-100 cells treated with 10 µM Bru + 1 µM Gem at 48 h as compared to the drugs alone (Fig. 8C,D).Fig. 8Combination effect of Bru and chemotherapeutic drugs on KKU-100 cell migration and invasion. (A, B) Representative images and their quantification KKU-100 cell migration exposed to 5 µM Bru, 5 µM Cis or 5 µM Bru + 5 µM Cis. (C, D) Representative images and their quantification KKU-100 cell migration exposed to 10 µM Bru, 1 µM Gem, or 10 µM Bru + 1 µM Gem. (E, F) Representative images illustrated KKU-100 cell invasion after being treated for 48 h with individual compounds or the combination. (G, H) Quantification of invasive cell number. Graphs represent mean ± SEM of four independent biological replicates with two technical duplicates each. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test. (****p < 0.0001 versus control; while ##p < 0.01, ###p < 0.001, and ####p < 0.0001 versus compared group as indicated by straight line). Combination effect of Bru and chemotherapeutic drugs on KKU-100 cell migration and invasion. (A, B) Representative images and their quantification KKU-100 cell migration exposed to 5 µM Bru, 5 µM Cis or 5 µM Bru + 5 µM Cis. (C, D) Representative images and their quantification KKU-100 cell migration exposed to 10 µM Bru, 1 µM Gem, or 10 µM Bru + 1 µM Gem. (E, F) Representative images illustrated KKU-100 cell invasion after being treated for 48 h with individual compounds or the combination. (G, H) Quantification of invasive cell number. Graphs represent mean ± SEM of four independent biological replicates with two technical duplicates each. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test. (****p < 0.0001 versus control; while ##p < 0.01, ###p < 0.001, and ####p < 0.0001 versus compared group as indicated by straight line). Furthermore, the effects of combining Bru with chemotherapeutic drugs, Cis and Gem, on the invasion of KKU-100 cells was investigated using transwell invasion assay. After incubation for 48 h, both Bru and chemotherapeutic drugs, Cis and Gem, considerably reduced KKU-100 cell invasion as compared with control group (Fig. 8E–H). Similar to the effects seen in cell migration, the inhibitory effects of the combination treatments (5 µM Bru + 5 µM Cis and 10 µM Bru + 1 µM Gem) were greater than either individual agent (Fig. 8E–H). Collectively, these findings suggested that co-treatment of Bru and standard chemotherapeutic agents, Cis and Gem, not only enhanced cytotoxicity but also significantly weakened the migratory and invasive potential of KKU-100 cells. Discussion Surgical resection remains the key curative treatment for patients with cholangiocarcinoma (CCA). Most patients, unfortunately, are diagnosed with the unresectable disease because of clinical silence30. Moreover, even in patients who undergo surgery, recurrence and metastasis are frequent. This underscores the need for more effective treatment strategies. One of the main alternative treatments for patients with advanced CCA is chemotherapy. The current first-line chemotherapy regimen in patients with advanced stage of CCA is a combination of Cis and Gem7. However, the therapeutic efficacy of these agents is often limited by the development of acquired drug resistance, which remains a major obstacle in CCA treatment8. The discovery of the more effective chemotherapy for CCA, along with finding novel strategies to overcome resistance and improve clinical outcomes, is needed to combat this lethal malignancy. Phytochemicals hold promise as anti-cancer agents owing to their capacity to induce programmed cell death in cancer. In the present study, we demonstrated the potent chemo-sensitizing potential of Bru, a chemical found in Brucea javanica, against CCA cells in vitro. Key findings of this study are i) Bru significantly enhanced the cytotoxic effect of Cis but exhibited an antagonistic effect when combined with Gem, ii) The enhanced toxicity in combination treatments is associated with intracellular ROS accumulation, iii) the combination of Bru and chemotherapeutic drugs, Cis and Gem, substantially induced depolarization of mitochondrial transmembrane potential in KKU-100 cells, iv) the combination of Bru and chemotherapeutic drugs, Cis and Gem, induced apoptosis in KKU-100 by simultaneous activation of the intrinsic and extrinsic pathways, and v) the combination of Bru and chemotherapeutic drugs, Cis and Gem, significantly suppressed the proliferative, migratory and invasive capabilities of KKU-100 cells. Previous reports have demonstrated that Bru exerts anticancer effects across various cancer cell types, including pancreatic, colorectal, hepatocellular, lung cancer and leukemia16,31–34. Consistent with these findings, our study found that cytotoxic effect of Bru in CCA cell lines (KKU-100 and KKU-452) was dose- and time-dependent. The estimated IC50 values of Bru in this work were close to previous reports on human intrahepatic cholangiocarcinoma cell line (Hucc-T1) and human liver cancer cell (Huh7)31,35. However, the IC50 of Bru in some cancer cells, such as pheochromocytoma and paraganglioma36, head and neck squamous cell carcinoma37, hematologic malignancies38 was less than the IC50 value we observed in CCA cells. These differences suggest that cellular sensitivity to Bru is highly cell-type dependent. Studies have shown that Bru acts as a chemosensitizing agent by enhancing the efficacy of chemotherapeutic agents like Cis or Gem in pancreatic cancer and lung cancer13,15, thereby highlighting its potential utility in combination therapy. Our findings support previous studies showing that Bru enhances the efficacy of chemotherapeutic agents by disrupting redox homeostasis, potentially through inhibition of antioxidant defense pathways in various types of cancer including lung cancer, breast cancer, endometrial adenocarcinoma cervical cancer and hepatoma13,39. In line with these observations, our study is the first to show that the combinatory effect of Bru is drug-dependent in KKU-100 CCA cells. This differential interaction may be explained by the distinct mechanisms of action of the chemotherapeutic agents, Cis and Gem, and the biological effects of Bru. The observed synergistic effect may be associated with Bru-induced intracellular oxidative stress and disruption of mitochondrial membrane potential, which is able to increase the susceptibility of cancer cells to DNA-damaging agents, such as Cis. These observations support the involvement of oxidative stress-associated mitochondrial dysfunction in the anticancer activity of Bru; however, the upstream molecular mechanisms responsible for these effects require further investigation. In contrast, Gem is a nucleoside analog that primarily targets DNA synthesis during the S-phase of the cell cycle40,41. The antagonistic interaction observed in our study may suggest that Bru-induced cellular stress responses or alterations in cell cycle dynamics could interfere with Gem’s activity. Additionally, the reduction in cellular proliferation caused by Bru may limit the incorporation of Gem into DNA, thereby lowering its cytotoxic effect. It is well established that excessive accumulation of cellular ROS affects several signal transduction pathways, particularly those involved with cancer cell progression and apoptosis42. Our results revealed that the combination of Bru and chemotherapeutic drugs, Cis and Gem, significantly induced intracellular ROS accumulation, supporting its potential as a novel treatment for CCA. The cytotoxic effects from the combination of Bru and chemotherapeutic drugs, Cis and Gem, was attenuated by ROS scavenger NAC. The cytoprotective effect conferred by NAC indicates that ROS play an important role in the chemo-sensitizing effects. Cancer cells generally maintain elevated ROS levels as compared to normal cells due to their high metabolic activity and proliferation rates. However, ROS accumulation, triggered by ROS-generating agents, such as the combination of Bru and chemotherapeutic drugs, Cis and Gem, can overwhelm cellular antioxidant defenses, leading to apoptosis43. Caspase-mediated apoptosis follows two main pathways, the intrinsic mitochondrial pathway and the extrinsic death receptor pathway. Activation of intrinsic apoptotic signaling pathway involves mitochondrial membrane permeabilization, resulting in the activation of caspase-9 and caspase-344,45. Meanwhile, caspase-8 plays a pivotal role in the extrinsic apoptotic signaling pathway via cell death receptors44. Both pathways come together at caspase-3, which are responsible for the execution phase of apoptosis. Our study demonstrated that the combined treatment of Bru and chemotherapeutic agents, Cis and Gem, led to significant activation of caspase-3, −8, and −9, as well as loss of ΔΨm, indicating simultaneous activation of both apoptotic pathways. Activation of the extrinsic apoptotic signaling pathway may contribute to mitochondrial-mediated apoptosis through Bid cleavage, which can serve as a molecular link between caspase-8 activation and the intrinsic apoptotic signaling pathway46,47. Former studies have demonstrated that Caspase-8-mediated truncation of Bid (tBid) promotes mitochondrial outer membrane permeabilization and subsequent activation of the intrinsic apoptotic cascade48. Future investigation on Bid and additional downstream effectors will be beneficial to uncover this hypothesis. Previous study also reported that mitochondrial permeability transition pore (MPTP) alteration involved in ΔΨm, where excessive cellular ROS is one of the main factors contributing MPTP49,50. Another study has shown that Bru inhibited growth and induced apoptosis in pancreatic cancer cells via JNK/p38 MAPK/NF-κB/Stat3/Bcl-2 signaling pathway (one of the stress-responsive pathways)16. These findings highlight the pivotal role of ROS in the enhanced cytotoxicity observed with Bru and chemotherapeutic agents, Cis and Gem, co-treatment in KKU-100 cells. Increased ROS level has been shown to induce mitochondrial dysfunction, leading to loss of ΔΨm and the activation of caspase-9 and caspase-3 resulting in enhanced chemosensitivity in CCA26. Moreover, ROS can also activate death receptor–mediated signaling, resulting in caspase-8 activation51. Accumulating evidence indicates that Bru suppresses antioxidant defense pathways via Nrf2 inhibition and disrupts cellular redox homeostasis in various cancer cell types, thereby enhancing oxidative stress and sensitizing cancer cells to cytotoxic induction13,39. Although Nrf2 inhibition has been proposed as a mechanism of Bru action in other malignancies, Nrf2 signaling was not directly evaluated in the present study. Therefore, its contribution to the observed effects remains inferential and the involvement of Nrf2-independent mechanisms still needs to be evaluated in future study. In addition to short-term cytotoxicity, we demonstrated that both Bru and chemotherapeutic agents exert long-term inhibitory effects on the clonogenic capacity of KKU-100 cells. The results were consistent with the previous study that Bru dramatically suppressed colony formation in pancreatic cancer cells15. Since 5 µM Cis alone already produces a near-maximal inhibition of colony formation (> 98%), the additional effect observed in the Bru + Cis combination appears limited under this condition. However, previous experiments showed that the Bru + Cis combination induced significantly greater cytotoxicity and apoptosis as compared with 5 µM Cis alone. These results indicate that the combination treatment exerts additional biological effects beyond colony formation inhibition and suggest a potentially meaningful therapeutic advantage. These findings raise the possibility that the concentration of Cis could potentially be reduced in combination with Bru while maintaining therapeutic efficacy, which may help minimize Cis-associated side effects. Metastasis is a hallmark of cancer and remains a major contributor to cancer-related death. The metastatic process involves interconnected and successive stages, including extracellular matrix degradation, cell movement, cell invasion and cell adhesion52,53. In addition, metastasis has been linked to the development of chemotherapy resistance in various cancer types54,55. A compound with the ability to block steps involved with metastasis could be a potential candidate for cancer chemotherapy. Prior research has shown that Bru can suppress the proliferation and metastasis of human laryngeal carcinoma through inhibiting epithelial-mesenchymal transition (EMT) via the JAK2/STAT3 signaling pathway56. Similarly, our wound healing and the transwell invasion assays revealed that Bru was able to suppress both migrative and invasive ability of KKU-100 cells. More importantly, simultaneous administration of Bru with chemotherapeutic drugs, Cis and Gem, produced a more pronounced anti-metastatic effect than individual drugs, suggesting that Bru may have therapeutic potential in controlling CCA metastasis. Conclusion The present study is the first to explore the combinatorial effect of Bru and the standard chemotherapeutic drugs, Cis and Gem, in human CCA cells. Our novel findings showed that Bru significantly synergized the cytotoxic effect of Cis but exhibited an antagonistic effect when combined with Gem, emphasizing the effect of Bru in combination therapy is context-dependent and varies according to the mechanism of the co-administered chemotherapeutic agent. The combination of Bru and chemotherapeutic agents, Cis and Gem, increased intracellular ROS levels in KKU-100 cells, contributing to apoptosis induction. These combinations induced apoptosis in KKU-100 cells by simultaneous activation of both the intrinsic and extrinsic apoptosis pathways. Additionally, our research demonstrated that combining Bru with chemotherapeutic drugs, Cis and Gem, reduced the colony formation and counteracted the migrative and invasive abilities of the CCA cells. All these findings provide evidence to support the novel roles of Bru as a promising anticancer candidate or adjuvant to current chemotherapeutic drugs for CCA. However, further investigations in vivo are needed to explore the use of Bru for CCA treatment. Supplementary Information Supplementary Information. Supplementary Information.